Serving the Community
At Vape One we understand the critical role pharmacies play in safeguarding public health and serving their communities. Pharmacists face immense responsibilities and are often stretched thin. We are here to support the sale of therapeutic vapes in full compliance with TGA regulations, while providing
​
-
No-questions-asked return policy
-
In-person training and dedicated customer support
-
Streamlined ordering process​
Registration
To stock our product, gain access to product information and customer support.
News and Updates
Our goal is to make your job easier by providing updates and summaries of the latest rules and regulations, as well as sharing research and publications from leading global health organizations. We’re committed to helping you stay informed and to supporting your community with accurate, reliable information.
Professional practice guidelines for pharmacists Nicotine dependence support
Last Updated: 1 October 2024
Download the guidebook below
​
Tobacco smoking remains the leading cause of preventable death and disability in Australia, contributing significantly to diseases such as cancer (especially lung cancer), chronic obstructive pulmonary disease (COPD) and cardiovascular disease.
Recent trends indicate a significant increase in exclusive vaping, as well as dual smoking and vaping, particularly among people under 35 years of age. Nicotine dependence can be a chronic, relapsing condition. Advice from pharmacists to patients about stopping smoking helps people to stop.
These guidelines are applicable to all practice settings in which pharmacists provide nicotine dependence support, including providing medicines available without a prescription. These guidelines focus on the management of nicotine dependence that may have developed as a result of smoking or vaping.
Providing support to a patient with nicotine dependence can vary based on the service delivery model of the pharmacy or health service and the education and training of the pharmacy or health service staff. Regardless of the service delivery model of the pharmacy or health service, pharmacists should offer brief advice to all people who smoke or vape.
Supporting smoking cessation: A guide for health professionals
Last Updated: 22 May 2024
Download the guidebook below
​
Tobacco smoking remains the leading cause of preventable death and disability in Australia, contributing significantly to diseases such as cancer (especially lung cancer), chronic obstructive pulmonary disease (COPD) and cardiovascular disease.
Recent trends indicate a significant increase in exclusive vaping, as well as dual smoking and vaping, particularly among people under 35 years of age. Nicotine dependence can be a chronic, relapsing condition. Advice from pharmacists to patients about stopping smoking helps people to stop.
These guidelines are applicable to all practice settings in which pharmacists provide nicotine dependence support, including providing medicines available without a prescription. These guidelines focus on the management of nicotine dependence that may have developed as a result of smoking or vaping.
Providing support to a patient with nicotine dependence can vary based on the service delivery model of the pharmacy or health service and the education and training of the pharmacy or health service staff. Regardless of the service delivery model of the pharmacy or health service, pharmacists should offer brief advice to all people who smoke or vape.
Latest Changes To The Regulation of Vapes
From 1 October 2024, and subject to state and territory government requirements:
​
-
Therapeutic vapes containing 20 mg/mL of nicotine or less will be available from participating pharmacies without a prescription where clinically appropriate, to adults aged 18 years and over.
-
In order for a pharmacist to supply a vape without a prescription a consultation must be conducted with the patient to ensure that a vaping good is the appropriate treatment option.
-
A prescription is required to dispense a therapeutic vape in some instances. This includes but may not be limited to instances where the patient is under 18 years of age, or for those who require a higher nicotine concentration.
Pharmacists cannot be compelled to stock or supply therapeutic vapes, regardless of whether a patient holds a prescription.
Product standards: unapproved therapeutic vapes
Product standards apply to all unapproved vaping goods lawfully available in Australia for smoking cessation or the management of nicotine dependence. This includes vaping substances, vaping substance accessories, vaping devices and vaping device accessories.
These standards have been designed to minimise the risks associated with the use of therapeutic vapes that may be supplied by pharmacists. Importers, manufacturers and sponsors must notify the TGA of compliance with these standards through a sponsor notice prior to importing or supplying the product.
It is important to note that even among therapeutic vapes that are compliant with these standards, there are no guarantees about their safety, quality, efficacy or performance. The long-term health risks of vapes are unclear and the evidence of their potential efficacy for smoking cessation or the management of nicotine dependence is currently limited.
Strengthened standards were published by the TGA in October 2024 and include new requirements for devices, ingredients, packaging and labelling. The strengthened standards will be implemented in stages during the first half of 2025. Once fully implemented, these strengthened standards will replace earlier standards which commenced on 1 January 2024.
Neither the current or strengthened standards apply to therapeutic cannabis vapes which are subject to separate requirements. More information about medical cannabis is available on the Medicinal Cannabis Hub.​​​
​
Schedule 3
(pharmacist-only)
supply requirements
Pharmacists can supply vapes where it is clinically appropriate to patients who:
​
-
are 18 years or over
-
require a nicotine concentration of 20mg/mL or less
-
provide informed consent, which includes informing the patient or patient’s carer that the therapeutic good is not a listed good or registered good.
Before supplying a therapeutic vape for smoking cessation or the management of nicotine dependence, a pharmacist must:
​
-
be satisfied that supply is clinically appropriate for smoking cessation or the management of nicotine dependence
-
request and sight evidence of the patient’s identity and age (cannot be supplied to a third party unless they are the patient's carer)
-
inform the patient that the goods are not included in the ARTG and obtain the patient’s informed consent
-
provide professional advice to the patient in relation to alternative registered (Australian Register of Therapeutic Goods) therapies, appropriate dose and frequency and interactions with other medicines
-
ensure the quantity of goods supplied by the pharmacist to the relevant patient does not exceed one month supply in one month
-
provide contact details about cessation support services to the patient
-
supply the goods in accordance with state and territory legislation and good pharmacy practice.
Rules relating to vape products vary between states and territories and could affect whether or not vapes can be lawfully prescribed, dispensed and supplied in your state or territory.
Other regulatory obligations include:
​
-
only dispensing up to 1 month supply to the patient per month
-
requesting evidence of patient’s identity and age in accordance with relevant state and territory legislation. However, there is no requirement to report this information to the TGA.
-
providing advice and contact details to the patient on alternative cessation supports and therapies
-
reporting any adverse events to the TGA
Pharmacists supplying unapproved therapeutic vaping goods as Schedule 3 (pharmacist only) medicines must use the TGA SAS-C notification pathway.
SAS-C notification must be:
​
-
provided by pharmacists for each instance of supply
-
made within 28 days of supply. Best practice is to provide the notification at the time of supply.
Schedule 4
(prescription medicine)
dispensing requirements
The supply of prescription only vapes must be accompanied by a valid SAS or AP approval or notification (or reference number) from the prescriber.
Pharmacists who dispense prescriptions for vapes can confirm the validity of the SAS or AP submission by using the TGA online validation tool or by contacting the prescriber.
Pharmacists must use the TGA’s SAS/AP online system to check the validity of AP approvals and SAS notifications.
​